CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
The Canadian Cancer Trials Group (CCTG) has now activated the symptom control trial SC29 evaluating high precision stereotactic body radiotherapy (SBRT) to conventional palliative radiotherapy (CRT) for patients with advanced cancer and a painful non-spine bone metastasis. SBRT represents a high dose treatment typically offered in the curative cancer setting; however, its role as a palliative treatment to improve pain for these patients is unknown.
The Canadian Cancer Trials Group (CCTG) is requesting applications for the volunteer position of Chair of the Patient Representative Committee.
Immunotherapy is an innovative type of cancer treatment that harnesses the patient's own immune system to recognize and eliminate cancer cells. In the last decade, the use of immunotherapy has increased exponentially, and it is now applied as the treatment of choice in many different cancer types. This popularity comes from the remarkable results seen in some patients treated with immunotherapy, which can lead to a cure in some cases and significantly prolong patient lives in others.
A new partnership between the Marathon of Hope Cancer Centres Network (MOHCCN) and the Canadian Clinical Trials Group (CCTG) will support three pan-Canadian research teams aiming to better understand how immunotherapies can best be used to increase survival, reduce toxicities and improve quality of life for cancer patients in Canada.
Melanoma is the deadliest form of skin cancer, and prior to 2010, outcomes were extremely poor for most patients with metastatic melanoma, where their cancer had spread to other parts of their body. Encouragingly, a class of treatments called immune checkpoint inhibitors (ICIs) dramatically improved survival for some patients, even leading to cures in some cases. However, some patients do not respond to ICI therapy and others experience severe side-effects.
